369 related articles for article (PubMed ID: 29480226)
1. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.
Lee K; Nguyen KD; Sun C; Liu M; Zafar F; Saetern J; Flierl A; Tetrud JW; Langston JW; Dickson D; Schüle B
J Parkinsons Dis; 2018; 8(1):93-100. PubMed ID: 29480226
[TBL] [Abstract][Full Text] [Related]
2. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
3. Cross-examining candidate genes implicated in multiple system atrophy.
Katzeff JS; Phan K; Purushothuman S; Halliday GM; Kim WS
Acta Neuropathol Commun; 2019 Jul; 7(1):117. PubMed ID: 31340844
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Huang Y; Song YJ; Murphy K; Holton JL; Lashley T; Revesz T; Gai WP; Halliday GM
Acta Neuropathol; 2008 Dec; 116(6):639-46. PubMed ID: 18936941
[TBL] [Abstract][Full Text] [Related]
5. Rapidly progressive multiple system atrophy in a patient carrying LRRK2 G2019S mutation.
Carrer T; Bonato G; Sandre M; Emmi A; Campagnolo M; Musso G; Carecchio M; Parchi P; Antonini A
Neurol Sci; 2024 Jan; 45(1):309-313. PubMed ID: 37752324
[TBL] [Abstract][Full Text] [Related]
6. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
9. Protein disulfide isomerase immunopositive glial cytoplasmic inclusions in patients with multiple system atrophy.
Honjo Y; Ito H; Horibe T; Takahashi R; Kawakami K
Int J Neurosci; 2011 Oct; 121(10):543-50. PubMed ID: 21689057
[TBL] [Abstract][Full Text] [Related]
10. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of LRRK2 in tauopathies.
Herbst S; Lewis PA; Morris HR
Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
[TBL] [Abstract][Full Text] [Related]
12. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.
Kiely AP; Ling H; Asi YT; Kara E; Proukakis C; Schapira AH; Morris HR; Roberts HC; Lubbe S; Limousin P; Lewis PA; Lees AJ; Quinn N; Hardy J; Love S; Revesz T; Houlden H; Holton JL
Mol Neurodegener; 2015 Aug; 10():41. PubMed ID: 26306801
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 variation and dementia with Lewy bodies.
Heckman MG; Soto-Ortolaza AI; Contreras MYS; Murray ME; Pedraza O; Diehl NN; Walton R; Labbé C; Lorenzo-Betancor O; Uitti RJ; van Gerpen J; Ertekin-Taner N; Smith GE; Kantarci K; Savica R; Jones DT; Graff-Radford J; Knopman DS; Lowe VJ; Jack CR; Petersen RC; Parisi JE; Rademakers R; Wszolek ZK; Graff-Radford NR; Ferman TJ; Dickson DW; Boeve BF; Ross OA
Parkinsonism Relat Disord; 2016 Oct; 31():98-103. PubMed ID: 27521182
[TBL] [Abstract][Full Text] [Related]
14. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
15. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
Sanchez-Contreras M; Heckman MG; Tacik P; Diehl N; Brown PH; Soto-Ortolaza AI; Christopher EA; Walton RL; Ross OA; Golbe LI; Graff-Radford N; Wszolek ZK; Dickson DW; Rademakers R
Mov Disord; 2017 Jan; 32(1):115-123. PubMed ID: 27709685
[TBL] [Abstract][Full Text] [Related]
16. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
17. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
18. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations.
Takanashi M; Funayama M; Matsuura E; Yoshino H; Li Y; Tsuyama S; Takashima H; Nishioka K; Hattori N
Acta Neuropathol Commun; 2018 Oct; 6(1):105. PubMed ID: 30333048
[TBL] [Abstract][Full Text] [Related]
19. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
20. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
